Acadia Pharmaceuticals (ACAD) Finished Goods (2016 - 2026)

Acadia Pharmaceuticals' Finished Goods history runs 11 years deep, the most recent figure standing at $33.2 million for Q1 2026.

• On a quarterly basis, Finished Goods rose 39.0% year-over-year to $33.2 million in Q1 2026; TTM through Mar 2026 was $33.2 million, a 39.0% increase from a year earlier, with the FY2025 full-year figure at $26.0 million, up 26.84% from the prior year.
• Finished Goods advanced to $33.2 million in Q1 2026 per ACAD's latest filing, from $26.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $33.2 million in Q1 2026 and bottomed at $1.6 million in Q1 2023.
• The 5-year median for Finished Goods is $7.6 million (2024), against an average of $12.7 million.
• Across the five-year window, Finished Goods dropped 7.75% in 2023 and soared 758.53% in 2024, its largest moves.
• Year by year, Finished Goods stood at $1.9 million in 2022, then soared by 159.66% to $5.0 million in 2023, then jumped by 309.14% to $20.5 million in 2024, then grew by 26.84% to $26.0 million in 2025, then gained by 27.81% to $33.2 million in 2026.
• Per Business Quant, the three latest ACAD Finished Goods figures stand at $33.2 million (Q1 2026), $26.0 million (Q4 2025), and $25.0 million (Q3 2025).